37 results about "Neuroblastic Tumor" patented technology

Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.

The invention relates to naturally or artificially synthesized iso-thiocyanates i.e. JC-5411 compounds and their use in treating and preventing malignant tumor, wherein the compounds can directly suppress the methylation of the gene promoter / 5-UTR area CpG DNA, directly inhibit the reactivity of histone deacethylases (HADC), selectively promote histone acetylation and methylation, then further recover the expression of genes with important functions that are shut abnormally in cancer cells, thus control the malignant proliferation of cancer cells.

The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.

Methods and compositions for treating neuroblastoma are disclosed.

The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.

The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreating carcinomas) and mesotheliomas.

The invention relates to an application of a propofol derivate, namely propofol succinic acid monoester sodium salt (I) in preparing anti-tumor drugs, in particular, the application thereof in preparing drugs for resisting breast cancer, liver cancer or neuroblastoma.

The invention provides a method for preparing antihuman Nogo-66 receptor protein vaccine. An hNgR gene in full size is obtained by the PCR amplification from human neurobalstoma (SK-N-SH) cDNA. The amplified segment is inserted in a cloning vector and is sub-cloned to an expression vector pET28a (+) containing six His labels to obtain a recombinant expression plasmid pET28a-NgR. The recombinant plasmid is transformed into a coli expression strain BL21 (DE3) for the induced expression to obtain hNgR protein. By closing the effect of NgR and blocking the effect of inhibitory factor, the NgR protein vaccine can promote the regeneration of neurons axon after the spinal cord injury, can reduce the tissue necrosis in a damage zone, can promote the functional recovery of the injured spinal cord and express that the NgR protein vaccine is provided with a potential value for treating the spinal cord injury. The defect that exogenous biological agent can be easily eliminated by an autoimmune system is avoided. In addition, the characters that the cellular immunity is mainly induced after the DNA vaccination of NgR and only few individuals can induce humoral immunity are overcome.

The invention provides a diaryl ethyl diether compound and a pharmaceutically acceptable hydrate or salt as well as a synthetic method and anti-tumor application thereof. A structural general formulais as shown in the description. A preparation method comprises the following steps: dissolving 3-hydroxy-2 nitropyridine into DMF, adding 1,2-dibromoethane and potassium carbonate, and carrying out reaction, so that a compound e is obtained; dissolving the compound e into a solvent DMF, then adding a substance (as shown in the description) and potassium carbonate, then heating, and carrying out reaction, so that a compound d is obtained; reducing the compound d by virtue of iron powder, so that a compound c is obtained; dissolving the compound c into acetonitrile solution, and carrying out bromination reaction, so that a product b is obtained; adding the compound b and 1-(1-t-butyloxycarboryl piperidine-4-yl) pyrazole-4-boronic acid pinacol ester into DME, then adding Pd(dppf)Cl2 and Cs2CO3 aqueous solution, and carrying out reaction, so that a compound a is obtained; and adding the compound a into dichloromethane, dropwise adding 1,4-dioxane solution of hydrogen chloride under ice-bath condition, and carrying out reaction, so that the product is obtained. The compound provided by the invention is novel in structure, has the effect of resisting to non-small cell lung cancer and neuroblastoma and has the antitumor activity equivalent to or better than that of a positive control crizotinib.

The invention belongs to the technical field of biomedicine, and relates to a novel target used for preventing enterovirus 71 infection, and applications thereof. According to the invention, SH-SY5Y is taken as the target cell, and RNA interference technology is adopted for down-regulation of expression of target cell host protein so as to search host factors capable of inhibiting EV71 infection of SH-SY5Y cells effectively and protect the functions of central nervous systems. It is fond by experiments that calcium-and inte-grin-binding protein, CIB1 molecular possesses significant importance in EV71 infection of SH-SY5Y, and down-regulation of expression of CIB1 is capable of inhibiting EV71 infection obviously. The invention also provides applications of CIB1 in preparing drugs used for preventing or treating EV71 infection.

The invention discloses a protopanaxadiol derivative and pharmaceutically-acceptable salts, esters or solvates thereof. The protopanaxadiol derivative and the pharmaceutically-acceptable salts, esters or solvates thereof have a structure shown in the formula I. The invention further discloses application of the protopanaxadiol derivative and the pharmaceutically-acceptable salts, esters or solvates thereof in the preparation of drugs for treating and/or preventing tumors, particularly cervical carcinoma, leukemia, neuroblastoma, prostatic carcinoma, liver cancer and mammary cancer.

A biamidoheterocyclic derivative with antineoplastic activity and its preparing process are disclosed. It can be used to treat cancers, such as chronic granulocyte leukemia, acute lymphocyte leukemia and melanotic cancer etc.

The invention relates to the technical field of biomedicine, and provides a new target for resisting entervirus type 71 infection and application. A human neuroblastoma cell (SH-SY5Y) is taken as a target cell, expression of host protein of the target cell is down-regulated by adopting an RNA interference technique to look for a host factor which can effectively inhibit the EV71-infected human neuroblastoma cell (SH-SY5Y), and therefore the function of a central nervous system is protected. Through experiments, it is found that a dynamin 1 (NDM1) plays an important role on the EV71-infected SH-SY5Y, and EV71 infection can be obviously inhibited by down-regulating expression of the DNM1. The invention provides application of the DNM1 in preparation of medicine for preventing or treating the entervirus type 71 infection.

Provided are substituted cyclic amine compounds, and pharmaceutically acceptable salts and pharmaceutical preparations thereof as an anaplastic lymphoma kinase (ALK) inhibitor. Also provided is the use of the compound and pharmaceutical preparations thereof in the preparation of drugs for the treatment and inhibition of diseases including non-small cell lung cancer (NSCLC), neuroblastomas, anaplastic large cell lymphoma (ALCL), liver cancer and other diseases caused by the rise of the ALK activity level.

The present invention relates to the field of pediatric or childhood tumor therapy. More specifically, the invention relates to the use of the allosteric activator of the calcium sensor receptor, cinacalcet, for the preparation of a pharmaceutical product for the treatment of neuroblastic tumors, particularly for the treatment of neuroblastomas, ganglioneuroblastomas and ganglioneuromas.

The present invention is aimed at providing a method for utilizing external gene operation to induce the intracerebral transplanted mesenchymal stem cell to implement directed differentiation and make it into neurone. Its technical scheme includes the following steps: (1). using self-body biological characteristics to separate, amplify the purify mesenchymal stem cell; (2). cloning brain-derived neurotrophic factor cDNA sequence from human neuroblast tumor cDNA library, constructing retroviral vector of recombinant human brain-derived neurotrophic factor gene and introducing the brain-derived neutrotrophic factor gene into mesenchymal stem cell; and (3). utilizing cerebral stereo-orientation method to make the mesenchymal stem cell modified by brain-derived neurotrophic factor gene be transplanted into brain. Under the induction of neurotrophic factor the ratio of defferentiating mesenchymal stem cell into neurone can be obviously raised. Said invention also provides its application value.

The invention discloses a traditional Chinese medicine extract for resisting neuroblastoma as well as a preparation process and an application of the traditional Chinese medicine extract. The traditional Chinese medicine extract, which is an extract of osmanthus fragrans lour, is obtained by extracting pressed and deoiled osmanthus fragrans lour cake by virtue of water and ethyl acetate sequentially. The traditional Chinese medicine extract disclosed by the invention, which is prepared from a single Chinese herbal medicine, is not only capable of inhibiting the proliferation of human bone marrow neuroblastoma cells, but also wide in raw material source; therefore, the traditional Chinese medicine extract is low in production cost, and is of great social and economic significance.